Product Description
Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor, Inc.’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life. (Sourced from: https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-united-states-government-agreement-to-purchase-additional-supply-of-sotrovimab/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous,Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Canada | Croatia | Czech | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Romania | Slovakia | Spain | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Vir Biotechnology
Company Location: SAN FRANCISCO CA 94158
Company CEO: George Scangos
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Denmark, Ghana, Greece, India, Indonesia, Nepal, Nigeria, Poland, Singapore, South Africa, Spain, Switzerland, Uganda, United Kingdom, United States, Vietnam
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: COVID-19|Severe Acute Respiratory Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RECOVERY | P3 |
Recruiting |
COVID-19|Severe Acute Respiratory Syndrome |
2026-06-30 |
|
| PROTECT-V | P3 |
Recruiting |
COVID-19 |
2024-07-01 |
|
| COMET-PACE | P2 |
Active, not recruiting |
COVID-19 |
2024-04-16 |
|
| NCT05210101 | P2 |
Completed |
COVID-19 |
2023-02-28 |